AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35317789
Drug: Standard Treatment
RxNorm normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard Treatment (ST), n=250, connected to the Florida Quitline for telephone-based treatment and receiving a 10-week supply of nicotine replacement therapy (NRT).
Trial: 36228777
Drug: Medication first
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication first arm (n = 226)
Trial: 34089546
Drug: Agomelatine (25–50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agomelatine (25–50 mg) with a guided sleep phase advance
Trial: 82282326
Drug: Ursodeoxycholic acid,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid, 250 to 300 mg/d
Trial: 82282326
Drug: Ursodeoxycholic acid,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid, 500 to 600 mg/d
Trial: 82282326
Drug: Ursodeoxycholic acid,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid, 900 to 1000 mg/d
Trial: 82282326
Drug: Ursodeoxycholic acid,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid, 10 to 12 mg/kg body weight
Trial: 38291017
Drug: Standard conservative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard conservative treatment
Trial: 36107505
Drug: Turmeric-boswellia formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turmeric-boswellia formulation (TBF) 1000 mg
Trial: 33025648
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg KLH immunization
Trial: 33025648
Drug: 1 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 μg KLH intradermal administration after immunization
Trial: 35465983
Drug: H7N9 IIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H7N9 IIV and seasonal quadrivalent influenza vaccine (IIV4) simultaneously, followed by H7N9 IIV three weeks later (Group 1)
Trial: 35465983
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of H7N9 IIV at three-week intervals after IIV4 alone (Group 2)
Trial: 35465983
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of IIV4 (Group 3)
Trial: 37369826
Drug: Empagliflozin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (25 mg/day)
Trial: 35241360
Drug: Over-the-counter diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Over-the-counter diet pills
Trial: 33645377
Drug: Test 1
RxNorm normalized name: Bar Test 10% Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test 1 (0.413/0.050 mg/day E3/TMG)
Trial: 33645377
Drug: Test 2
RxNorm normalized name: Methitest 25mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test 2 (0.311/0.090 mg/day E3/TMG)
Trial: 33645377
Drug: Test 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test 3 (0.209/0.137 mg/day E3/TMG)
Trial: 33907099
Drug: XELOX (capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XELOX (capecitabine 1,000 mg/m2; twice daily for 14 days with oxaliplatin 130 mg/m2 on day 1, every 21 days)
Trial: 33907099
Drug: DX (capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DX (capecitabine 1,000 mg/m2; twice daily for 14 days with docetaxel 75 mg/m2 on day 1, every 21 days)
Trial: 35658487
Drug: Rucaparib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rucaparib 600 mg twice a day
Trial: 34013747
Drug: Caffeine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (5 mg·kg body wt‐1)
Trial: 34013747
Drug: Caffeine +
RxNorm normalized name: Voost Energy Caffeine + B Vitamin Complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine + Acetaminophen (Caffeine 5 mg·kg body wt‐1 + Acetaminophen 1,500 mg)
Trial: 34013747
Drug: Acetaminophen (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (1,500 mg)
Trial: 35414203
Drug: Tablet-based fatigue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based fatigue education and prescription program (FatigueUCope)
Trial: 36370124
Drug: Placebo (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (control treatment)
Trial: 34102418
Drug: Active rTMS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active rTMS (1 Hz, 110% motor threshold, 1200 pulses/session) combined with daily gait training
Trial: 34102418
Drug: Sham rTMS
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham rTMS combined with daily gait training
Trial: 32114477
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA) plus metformin
Trial: 35492335
Drug: Nitazoxanide (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitazoxanide (500 mg, 3 times daily for 5 days)
Trial: 34728434
Drug: Suture button
RxNorm normalized name: button mushroom extract
DrugBank: Cultivated mushroom (DB10544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suture button suspension (SBS)
Trial: 34997835
Drug: Fixed-Dose Combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-Dose Combination of Pitavastatin/Valsartan 4/160 mg
Trial: 33587674
Drug: LipiFlow treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LipiFlow treatment in LipiFlow-surgery eye
Trial: 33587674
Drug: LipiFlow treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LipiFlow treatment in LipiFlow-nonsurgery eye
Trial: 32604430
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (30 minutes daily)
Trial: 1994041002
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) 250 mg twice a day
Trial: 35358154
Drug: 2-g bolus
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-g bolus of tranexamic acid (TXA)
Trial: 35358154
Drug: 1-g bolus
RxNorm normalized name: phenylbutazone
DrugBank: Phenylbutazone (DB00812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1-g bolus plus 1-g infusion of tranexamic acid (TXA) over 8 hours
Trial: 33629488
Drug: Topical eflornithine
RxNorm normalized name: eflornithine Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical eflornithine cream twice daily for 16 weeks
Trial: 33629488
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of topical eflornithine cream and long‐pulsed Nd‐YAG laser for 16 weeks
Trial: 32135143
Drug: Expedited partner
RxNorm normalized name: Milkthistle Fruit (Silybum Marianum L. Gaertner)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expedited partner therapy prescription received
Trial: 32135143
Drug: Willingness to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Willingness to dispense expedited partner therapy prescription
Trial: 32135143
Drug: Cost of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost of azithromycin 1000 mg for treatment of chlamydia
Trial: 32135143
Drug: Cost of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost of cefixime 400 mg for treatment of gonorrhea
Trial: 616774609
Drug: Abdominal application
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abdominal application of traditional Chinese medicine combined with chewing gum
Trial: 616774609
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment and nursing care (Control)
Trial: 32543120
Drug: Edaravone 60
RxNorm normalized name: edaravone 60 MG in 100 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edaravone 60 mg (therapeutic dose)
Trial: 32543120
Drug: Edaravone 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edaravone 300 mg (supratherapeutic dose)
Trial: 35618299
Drug: Physical education
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical education intervention program (three 10-minute weekly medium- to high-intensity activities for one academic year)
Trial: 33617910
Drug: Sequential Boost
RxNorm normalized name: BOOST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential Boost (SEB)
Trial: 35927580
Drug: Levodopa (L-DOPA;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa (L-DOPA; 250 mg)
Trial: 36484921
Drug: Shexiang Baoxin
RxNorm normalized name: CAMPHOR (NATURAL) 30.53 mg / MENTHOL 40.71 mg / METHYL SALICYLATE 25.95 mg TOPICAL PLASTER [SheXiang ZhuangGu Gao]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shexiang Baoxin Pill combined with home‐based exercise training based on conventional drugs for 12 weeks
Trial: 36484921
Drug: Conventional drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drugs combined with home‐based exercise training for 12 weeks
Trial: 36484921
Drug: Conventional drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drug treatment only
Trial: 33899331
Drug: Near-infrared light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Near-infrared light (NIL) therapy combined with meibomian gland expression (MGX)
Trial: 33899331
Drug: Intense pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense pulsed light (IPL) therapy combined with meibomian gland expression (MGX)
Trial: 35445847
Drug: vonoprazan 10
RxNorm normalized name: vonoprazan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vonoprazan 10 mg every other day + clopidogrel 75 mg daily
Trial: 35445847
Drug: vonoprazan 10
RxNorm normalized name: vonoprazan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vonoprazan 10 mg daily + clopidogrel 75 mg daily
Trial: 35445847
Drug: clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clopidogrel 75 mg daily
Trial: 35445847
Drug: vonoprazan 10
RxNorm normalized name: vonoprazan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vonoprazan 10 mg every other day
Trial: 35445847
Drug: vonoprazan 10
RxNorm normalized name: vonoprazan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vonoprazan 10 mg daily
Trial: 33248135
Drug: Immediate laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate laser treatment
Trial: 33382385
Drug: Desloratadine citrate
RxNorm normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desloratadine citrate disodium (DCD, 8.8 mg/day) + Vitamin D3 nasal drops (1.5x10^6 IU, once/week) for four weeks
Trial: 33382385
Drug: Desloratadine citrate
RxNorm normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desloratadine citrate disodium (DCD, 8.8 mg/day)
Trial: 35022283
Drug: Wet-cupping therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wet-cupping therapy (hijama)
Trial: 33547784
Drug: Placebo/Atacicept 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo/Atacicept 150 mg
Trial: 631198356
Drug: Intensive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive blood pressure lowering treatment
Trial: 631198356
Drug: Standard blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard blood pressure lowering treatment
Trial: 34488034
Drug: Pharmacist-led systematic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led systematic review of medications for PIM detection using explicit and implicit methods; communication of appropriate therapeutic strategies to physicians.
Trial: 34488034
Drug: Pharmacist-led systematic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led systematic review of medications for PIM detection.
Trial: 34225463
Drug: Core formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Core formulation regimen (test group)
Trial: 33236329
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (GO) in combination with conventional induction chemotherapy
Trial: 33236329
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (GO) as monotherapy for newly diagnosed AML
Trial: 32432489
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (GO) as monotherapy for R/R AML
Trial: 36253105
Drug: Levodopa/carbidopa 300/75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa/carbidopa 300/75 mg daily for 80 weeks (early-start group)
Trial: 36253105
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 40 weeks followed by levodopa/carbidopa 300/75 mg daily for 40 weeks (delayed-start group)
Trial: 36007448
Drug: EWA program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EWA program (two‐year specialized woman only treatment including psychiatric, interpersonal and family concerns)
Trial: 36007448
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) in a mixed gender setting
Trial: 34085324
Drug: Peripheral muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral muscle strength training (PMT) and respiratory muscle strength training (RMT) associated with conventional physical therapy, one session a day for 5 days.
Trial: 34085324
Drug: Conventional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physical therapy, one session a day for 5 days.
Trial: 33740734
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/m² (D75)
Trial: 35606823
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care program comprising twelve weekly in-clinic physiotherapy sessions.
Trial: 32089338
Drug: Bilateral mental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral mental incisive nerve block (MINB) of 1.8 mL of 2% lidocaine with 1:80,000 epinephrine
Trial: 32089338
Drug: Unilateral mental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unilateral mental incisive nerve block (MINB) of 1.8 mL of 2% lidocaine with 1:80,000 epinephrine
Trial: 35666322
Drug: Etidronate (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidronate (20 mg/kg for 2 weeks on and 10 weeks off, orally for 12 months)
Trial: 32886811
Drug: 200,000 U
RxNorm normalized name: nystatin 200,000 UNT Oral Lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200,000 U polymyxin B + 40 mg neomycin solution in normal saline (antibiotic)
Trial: 35804078
Drug: Reflex locomotion
RxNorm normalized name: Cuscuta reflexa extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reflex locomotion therapy (RLT)
Trial: 33934208
Drug: Intravesical instillation
RxNorm normalized name: ADSTILADRIN Suspension for Intravesical Instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical instillation (II) of heparin and alkalinized lidocaine
Trial: 36595123
Drug: Cabozantinib 60
RxNorm normalized name: cabozantinib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabozantinib 60 mg orally once daily
Trial: 33906954
Drug: Home-based program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based program with health coaching (8-week intervention, video-guided exercises 6 times a week, weekly health coaching over the telephone)
Trial: 33713841
Drug: 4-month treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-month treatment regimen
Trial: 33713841
Drug: 6-month standard
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month standard treatment regimen
Trial: 34757964
Drug: Various pharmacological
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various pharmacological interventions over the years including anticholinesterases (physostigmine, neostigmine), immunosuppressants (prednisone, azathioprine), intravenous immune globulin, mycophenolate, cyclosporine, tacrolimus, monoclonal antibodies (rituximab, eculizumab)
Trial: 34757964
Drug: Immunosuppressant pharmacological
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressant pharmacological interventions
Trial: 34757964
Drug: Newer immunosuppressant
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Newer immunosuppressant drugs (mycophenolate, cyclosporine, tacrolimus)
Trial: 34757964
Drug: Monoclonal antibodies
RxNorm normalized name: Monoclonal antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibodies (rituximab, eculizumab)
Trial: 34757964
Drug: Randomized clinical
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized clinical trial of drug therapy for myasthenia gravis
Trial: 36229663
Drug: Tebentafusp (gp100×CD3),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tebentafusp (gp100×CD3), a soluble T cell receptor bispecific
Trial: 35968511
Drug: 60 mg/day
RxNorm normalized name: cabozantinib s-malate 60 mg/day (20 mg x 3/day) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/day tandospirone
Trial: 35968511
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day tandospirone
Trial: 32632491
Drug: 0.01 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01 mg/kg intravenous THC
Trial: 32632491
Drug: 0.03 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03 mg/kg intravenous THC
Trial: 35251396
Drug: Traditional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatment group
Trial: 34891167
Drug: E-cigarette flavors
RxNorm normalized name: blackberry flavor
DrugBank: Blackberry (DB10628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E-cigarette flavors (green apple, strawberry, chocolate, vanilla, menthol, koolada, peppermint, spearmint, subtle tobacco, full‐flavored tobacco) with nicotine formulations (free-base, salt)
Trial: 33394598
Drug: Early enteral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early enteral nutrition (EN), specific dosage and duration not mentioned.
Trial: 33394598
Drug: Restrictive dose
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive dose EN into the stomach after initial resuscitation, specific dosage not mentioned.
Trial: 33982511
Drug: Objective performance
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Objective performance criteria in post-marketing evaluation of TCM injections
Trial: 34601386
Drug: Hypnosis intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypnosis intervention (four weekly sessions plus treatment-as-usual)
Trial: 34477330
Drug: Dimethyl fumarate
RxNorm normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dimethyl fumarate (480 mg/day)
Trial: 33067169
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 800 mg
Trial: 35807801
Drug: Probiotic treatment
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic treatment (Lactobacillus acidophilus LA‐5, Lactiplantibacillus plantarum UBLP‐40, Bifidobacterium animalis subsp. lactis BB‐12, Saccharomycesboulardii Unique‐28)
Trial: 32340871
Drug: Usual-dose aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usual-dose aspirin (325 mg)
Trial: 34273468
Drug: Extreme weekly
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Extreme weekly locoregional hypofractionated radiation (HFRT)
Trial: 32307005
Drug: Continuing statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuing statin treatment at usual dosage
Trial: 34733238
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist pretreatment
Trial: 34733238
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no GnRH agonist pretreatment)
Trial: 33022417
Drug: aPDT (Photodithazine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aPDT (Photodithazine, 200 mg/L, 6 sessions, 3 times a week for 15 days)
Trial: 33570770
Drug: Peak CK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peak CK within 1st tertile (CK ≤259 U/L; n=1127 patients)
Trial: 33570770
Drug: Peak CK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peak CK within 2nd tertile (CK 260 to 990 U/L; n=1119 patients)
Trial: 33570770
Drug: Peak CK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peak CK within 3rd tertile (CK ≥991 U/L; n=1122 patients)
Trial: 32453306
Drug: LCPT 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCPT 2 mg (morning dosing)